• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

Hide Search
Shopping Cart
Show SearchSearch
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
    • Our Impact
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
    • Interactive Tool
    • Other Educational Tools
    • LactRx App
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Refer a Patient
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
  • Donate
  • Contact
  • Show SearchSearch

Chlordiazepoxide (Librium®)

December 1, 2024

Selected References:  

  • Andrade C. 2022 Psychotropic drugs with long half-lives: implications for drug discontinuation, occasional missed doses, dosing interval, and pregnancy planning. J Clin Psychiatry, 83:22f14593. 
  • Athinarayanan P, et al. 1976. Chlordiazepoxide withdrawal in the neonate. Am J Obstet Gynecol, 124:212-213. 
  • Crombie DL, et al. 1975. Fetal effects of tranquilizers in pregnancy. New Eng J Med, 293:198-199. 
  • Czeizel A. 1988. Lack of evidence of teratogenicity of benzodiazepine drugs in Hungary. Reprod Toxicol, 1:183-188. 
  • Czeizel AE, et al. 1997. Teratologic evaluation of 178 infants born to mothers who attempted suicide by drugs during pregnancy. Obstet Gynecol, 90:195-201. 
  • Czeizel AE, et al. 2004. A population-based case-control study of oral chlordiazepoxide use during pregnancy and risk of congenital abnormalities. Neurotoxicology & Teratology, 26(4):593-598. 
  • Czeizel AE, Mosonyi A. 1997. Monitoring of early human fetal development in women exposed to large doses of chemicals. Environ Mol Mutagen, 30:240-244.  
  • Gidai J, et al. 2008. A study of the teratogenic and fetotoxic effects of large doses of chlordiazepoxide used for self-poisoning by 35 pregnant women. Toxicol Ind Health, 24(1-2):41-51. 
  • Hartz SC, et al. 1975. Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development and childhood mortality. New Eng J Med, 292:726-728. 
  • Hughes JM. 1964. Failure to ejaculate with chlordiazepoxide. Am J Psychiatry, 121:610-611. 
  • Martino V, Mas M, Davidson JM. 1987. Chlordiazepoxide facilitates erections and inhibits seminal emission in rats. Psychopharmacology, 91:85-89. 
  • Milkovich L, Van den Berg BJ. 1974. Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development. New Eng J Med, 291:1268-1271.  
  • Stirrat GM, et al. 1974. Transplacental passage of chlordiazepoxide. Br Med J, 2:729. 

Footer

               

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Constipation
  • Coronavirus (COVID-19)
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Lupus
  • Multiple Sclerosis
  • Non-Radiographic Axial Spondyloarthritis
  • Psoriasis
  • Psoriatic Arthritis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists

Copyright © 2025 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.